Oasmia Pharmaceutical Ab (0N4A)
LSE
Oasmia Pharmaceutical AB (publ) Interim report for the period May 2017 – January 2018 Commercial focus and lower cost base THIRD QUARTER November 1, 2017 – January 31, 2018 Consolidated net...
Oasmia Pharmaceutical’s Docecal program achieves significant development milestone Oasmia Pharmaceutical AB announces that all patients have been treated in the two ongoing studies with...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 5.2065 | 5.2065 | 5.2065 | 3417 | 5.2065 | DE |
4 | 0 | 0 | 5.2065 | 5.2065 | 5.2065 | 569 | 5.2065 | DE |
12 | 0 | 0 | 5.2065 | 5.2065 | 5.2065 | 174 | 5.2065 | DE |
26 | 0 | 0 | 5.2065 | 5.2065 | 5.2065 | 79 | 5.2065 | DE |
52 | 0 | 0 | 5.2065 | 5.2065 | 5.2065 | 165 | 5.2065 | DE |
156 | 0 | 0 | 5.2065 | 5.2065 | 5.2065 | 2280 | 5.2065 | DE |
260 | 1.2765 | 32.4809160305 | 3.93 | 11.435 | 3.921 | 3887 | 5.49742786 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約